EUVIMEDEUVIMED entdecken
Crossref

Crystal structure of SARS-CoV-2 main protease (Mpro) mutants in complex with the non-covalent inhibitor CCF0058981

Haihai Jiang, Xiaofang Zou, Xuelan Zhou, Jin Zhang, Jian Li

Biochemical and Biophysical Research Communications · 2024-01 · 692 · 149352

DOI: 10.1016/j.bbrc.2023.149352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024-01. Verfasst von Haihai Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province, Key Research and Development Program of Jiangxi Province, Guangxi Key Research and Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS-CoV-2 constantly circulates and evolves worldwide, generating many variants and posing a menace to global health. It is urgently needed to discover effective medicines to treat the disease caused by SARS-CoV-2 and its variants. An established target for anti-SARS-CoV-2 drug discovery is the main protease (Mpro), since it exerts an irreplaceable action in viral life cycle. CCF0058981, derived from ML300, is a non-covalent inhibitor that exhibits low nanomolar potency against SARS-CoV-2 Mpro and submicromolar anti-SARS-CoV-2 activity, thereby providing a valuable starting point for drug design. However, structural basis underlying inhibition of SARS-CoV-2 Mpro by CCF0058981 remains undetermined. In this study, the crystal structures of CCF0058981 in complex with two SARS-CoV-2 Mpro mutants (M49I and V186F), which have been identified in the recently emerged Omicron subvariants, were solved. Structural analysis defined the pivotal molecular factors responsible for the interactions between CCF0058981 and these two Mpro mutants, and revealed the binding modes of CCF0058981 to Mpro M49I and V186F mutants. These data not only provide structural insights for SARS-CoV-2 Mpro inhibition by CCF0058981, but also add to develop effective broad-spectrum drugs against SARS-CoV-2 as well as its variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAntiviral AgentsProtease InhibitorsViral Nonstructural ProteinsMolecular Docking SimulationImidazolesTriazolesCoronavirus 3C Proteases

Stichwörter der Autor:innen

CCF0058981Main proteaseNon-covalent inhibitorSARS-CoV-2Structural basis

Substanzen

Antiviral AgentsProtease InhibitorsViral Nonstructural Proteins2-(benzotriazol-1-yl)-N-((3-chlorophenyl)methyl)-N-(4-(1H-imidazol-4-yl)phenyl)acetamideImidazolesTriazoles3C-like proteinase, SARS-CoV-2Coronavirus 3C Proteases

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China.
  • College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China.
  • Jiangxi Jmerry Biopharmaceutical Co., Ltd., Ganzhou, 341000, China; Shenzhen Crystalo Biopharmaceutical Co., Ltd., Shenzhen, 518118, China.
  • School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China. Electronic address: zhangxiaokong@hotmail.com.
  • College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, 341000, China. Electronic address: rmsl_2040@163.com.

Förderung

  • Natural Science Foundation of Jiangxi Province
  • Key Research and Development Program of Jiangxi Province
  • Guangxi Key Research and Development Program
  • Gannan Medical University
  • National Natural Science Foundation of China
  • Double Thousand Plan of Jiangxi Province

Zitieren

APA

Jiang, H., Zou, X., Zhou, X., Zhang, J., & Li, J. (2024). Crystal structure of SARS-CoV-2 main protease (Mpro) mutants in complex with the non-covalent inhibitor CCF0058981. Biochemical and Biophysical Research Communications, 692, 149352. https://doi.org/10.1016/j.bbrc.2023.149352

Vancouver

Jiang H, Zou X, Zhou X, Zhang J, Li J. Crystal structure of SARS-CoV-2 main protease (Mpro) mutants in complex with the non-covalent inhibitor CCF0058981. Biochemical and Biophysical Research Communications. 2024;692:149352. doi:10.1016/j.bbrc.2023.149352

BibTeX
@article{Jiang2024,
  author = {Jiang, Haihai and Zou, Xiaofang and Zhou, Xuelan and Zhang, Jin and Li, Jian},
  title = {Crystal structure of SARS-CoV-2 main protease (Mpro) mutants in complex with the non-covalent inhibitor CCF0058981},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2024},
  volume = {692},
  pages = {149352},
  doi = {10.1016/j.bbrc.2023.149352}
}
Kostenlos starten →